• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
160029 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
4 J3 w0 @7 N4 @; P, x8 D0 r3 V/ B  K5 S0 A# g
. E, H& T& O* k' N
Sub-category:* B3 _+ `, y2 _* |. |. r( ^2 T
Molecular Targets & M4 d( ?" Y3 n2 O2 a

2 n$ H) m5 |6 ~
0 q7 {6 d3 z( ?, l. ~Category:
8 F5 |6 K7 O* Q) XTumor Biology
1 C( g9 M0 k' J( @7 [1 p0 o- ~

" P+ @* U6 F0 U9 S( YMeeting:
4 d3 S7 r" A2 h- K, V" A* G2011 ASCO Annual Meeting
  e: {' ?. Q0 y" H) Q1 D$ {/ W+ B0 d1 u# ]" s
) g  P6 j2 _" r$ ^& I
Session Type and Session Title:
* `% P( F$ Z5 ?8 i  R& TPoster Discussion Session, Tumor Biology % ~3 s, S- t# J1 o0 `# k( @
7 g9 j' e+ K' z
9 r: i5 j/ e. K$ a
Abstract No:. K" A( P( i" R0 I- O6 R$ c( P
10517 ) J% {$ _$ H8 T- l. P0 T
8 ~7 x' W2 z# s0 l

( D! V9 K; s6 q2 v& h: _6 y3 zCitation:
0 T0 _# V' d  p0 D; bJ Clin Oncol 29: 2011 (suppl; abstr 10517)
! [6 N/ ]" w# K* i) ~
9 V2 U6 {! g6 P) b/ _% x1 r7 o. Y) f
Author(s):
" V  s  c" d/ m3 H: g, Y: o0 LJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 2 @( H4 u/ c" ?. L

/ D+ x- `2 L; `7 `+ @
0 f2 e( l( G% V4 |% c* j. k+ a3 Z* a3 ~
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.8 v& X. ?" r3 r6 q
" m  _( a$ d- T6 x
Abstract Disclosures
$ u4 d" t, K! u* ]# U$ R+ \3 J6 I; J# O" M7 n, J  f/ J
Abstract:
" o$ V3 Q( N! f1 M6 {8 X- r) I4 O8 @% ]3 o9 f

8 i4 a8 w$ _( E6 ]Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. d& w( w* B# n. y  @
6 F* d% N: f$ y  d4 @ 1 ~; t6 j0 O3 i7 S* C: k
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 : T4 ^9 N- d6 e
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
& H2 V; V5 t+ b+ Q5 W
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
$ h6 n+ j/ r) v; T' J易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。: ?" Q+ u# c( I( A
ALK一个指标医院要900多 ...

9 a2 X! C( K1 V% Z" a! x9 j平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?. L6 t; o8 F; Y- A2 F

9 _; P2 [4 S8 C' }/ c现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表